Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01526889) looked at a treatment called LFG316 compared to conventional therapy in people with uveitis, which is an inflammatory condition affecting the eye. A total of 25 people took part in the main treatment period — 18 in the LFG316 group and 7 in the conventional therapy group. Of these, 16 in the LFG316 group and all 7 in the conventional therapy group completed that period. A smaller follow-on extension period involved 5 participants from the LFG316 group only, of whom 4 completed it. The trial was measuring things like changes in eye cloudiness (called vitreous haze), visual acuity (sharpness of vision), inflammation inside the eye (measured by cells in the front chamber), and the presence of lesions at the back of the eye. The reported data shows that, for the main response measures during the treatment period, 3 out of 18 participants in the LFG316 group and 3 out of 7 in the conventional therapy group met at least one of the individual response criteria (such as meaningful improvements in eye cloudiness or vision). For the stricter measure of full remission — meaning very low inflammation scores, no lesions, and no need for immune-suppressing medicines — 2 participants in the LFG316 group and 0 in the conventional therapy group met those criteria. Regarding vision scores (measured by letters read on a standardised eye chart), the reported data shows average scores across time points ranging roughly from 65 to 80 letters in the LFG316 group and from 77 to 80 letters in the conventional therapy group. Small numbers of participants in both groups were reported to have macular swelling (fluid at the centre of the retina) and lesions at the back of the eye at various points during the trial. It is worth noting that this was a small trial, and the numbers of participants in each group were quite different, which limits how much can be read into any comparison between the two groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older (male or female)
- You have active inflammation inside at least one eye (called non-infectious uveitis) that needs stronger treatment to control it
- You have a specific type of clouding in the jelly-like part of your eye (called vitreous haze), or you have damage to the back of your eye caused by the inflammation
- Your current eye inflammation medicine has recently been reduced or stopped at the time of receiving the study treatment
- Your vision in the eye being studied is at least 20/400 (you can read at least 20 letters on a special eye chart)
- If you are a woman, you must not be pregnant or breastfeeding, and must be using reliable birth control unless you have gone through menopause
- You are able to understand and agree to participate in the study, and are able to follow the study instructions
Who may not be able to join:
- Your eye inflammation is so severe that the study doctor feels it would be too risky to try an experimental treatment
- You have received certain biological medicines (given by injection into the eye, vein, or under the skin) within the past 4 to 12 months, depending on which medicine you received
- You have a history of eye inflammation caused by an infection, or a serious eye infection called endophthalmitis, in either eye
- You have a history of a detached retina in either eye
- You have had eye surgery, an injection into or around the eye, or laser treatment in the study eye within the past 90 days
- You have a cataract in the study eye that is expected to get in the way of the study or will likely need surgery during the study period
- Your type of eye inflammation is one that may go away on its own without treatment (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Response Rate for the Individual Response Criteria - in the Study Eye; Number of Participants With Remission in Study Eye - Treatment Period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.